Breast Cancer Patient Issues in Family Practice: An Interactive Session
description
Transcript of Breast Cancer Patient Issues in Family Practice: An Interactive Session
![Page 1: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/1.jpg)
Breast Cancer Patient Issuesin Family Practice:
An Interactive Session
![Page 2: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/2.jpg)
AcknowledgementsContent Development Committee
Sunil Verma, MD, MSEd, FRCPC Lisa Del Giudice, MSc, MD, CCFP Medical Oncologist, StaffDivision of Medical Department of Family MedicineOncology/Hematology Sunnybrook & Women's College Toronto Sunnybrook Regional Health Sciences Centre Cancer Centre Assistant ProfessorAssistant Professor, University of Toronto University of Toronto Toronto, OntarioToronto, [email protected]
Novartis Pharma Canada Inc gratefully acknowledges the commitment and dedication of the Content Development Committee to the development of this program
![Page 3: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/3.jpg)
Objectives
To recognize the risk of breast cancer recurrence and the common health problems faced by women with history of breast cancer
To review the requirements for complete follow-up care of women with history of breast cancer
To discuss the recent advances in the field of breast cancer, specifically in the arena of endocrine therapies
To describe the reasons for referrals back to the cancer centre for women with history of breast cancer
![Page 4: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/4.jpg)
National Cancer Institute of Canada/www.cancer.ca.Fisher et al. J Natl Cancer Inst Monographs 2001.
*American Joint Committee on Cancer. Handbook for Staging of Cancer 1993.
Breast Cancer
2004 breast cancer rates from the National Cancer Institute of Canada
– 21,200 new cases diagnosed in Canada– 5,200 deaths
Second leading cause of cancer death in women Outcome is directly related to stage at diagnosis, eg,
survival after 5 years* – Stage I disease 95%– Stage II disease 70%-85%– Stage III disease 50%-52%– Stage IV disease 17%
![Page 5: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/5.jpg)
2004 Canadian Breast Cancer Incidence Rates
Of the 21, 200 new cases
16,700 (79%) were
age ≥50 years 11,000 (52%) were
age ≥60 years
www.cancer.ca
![Page 6: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/6.jpg)
Mortality Rates in Patients With Breast Cancer Aged 50 to 69 Years
0
Year
105
90
75
60
45
30
15
1950 1960 1970 1980 1990 2000
An
nu
al d
eath
rat
ep
er
10
0,0
00
wo
men
UK
USA
Reprinted with permission from Elsevier Science. Lancet 2000.
![Page 7: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/7.jpg)
Breast Cancer Presentation
Early Breast Cancer
Locally AdvancedBreast Cancer
Metastatic Breast Cancer
![Page 8: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/8.jpg)
Early Breast Cancer Treatment Schema
SURGERY
AdjuvantChemotherapy
AdjuvantRadiation
AdjuvantEndocrine
![Page 9: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/9.jpg)
Early Breast Cancer Treatment Schema
SURGERY
Follow-Up
AdjuvantChemotherapy
AdjuvantRadiation
AdjuvantEndocrine
![Page 10: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/10.jpg)
Case No. 1
45-year-old female patient R breast lump originally diagnosed March 2004 R breast lumpectomy and node dissection 6 weeks
ago Pathology
– 2.5 cm size– Tumour Grade II/III – Estrogen receptor -ve/Progesterone receptor -ve
(hormone receptor negative)– Lymph nodes 3/12 involved
![Page 11: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/11.jpg)
Case No. 1
What is her recurrence risk? – Without any further treatment?– With chemotherapy?
![Page 12: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/12.jpg)
Prognostic Factors
In order for us to assess the recurrence risk we need to review certain prognostic factors
These prognostic factors include– Lymph node status– Tumour size– Tumour grade– Receptor status
![Page 13: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/13.jpg)
Case No. 1: Recurrence Risk (10 yr)Benefit from Chemotherapy
0
10
20
30
40
50
60
70
58.7%
33.4%
Per
cen
tag
e o
f p
atie
nts
(%
)
No additional therapy
Chemotherapy
![Page 14: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/14.jpg)
Case No. 1: Survival Benefit from Chemotherapy
(Alive in 10 years)
0
10
20
30
40
50
60
70
80
51.0%
70.1%
Per
cen
tag
e o
f p
atie
nts
(%
)
No additional therapy
Chemotherapy
![Page 15: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/15.jpg)
Case No. 1: Conclusion
Adjuvant chemotherapy results in– Lowering the recurrence risk, and– Improvement in survival
The patient in this case with early breast cancer should be considered for a medical oncology opinion for possible adjuvant chemotherapy
![Page 16: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/16.jpg)
Exciting Advances in Breast Cancer Management
Chemotherapy
Molecular therapy
Endocrine therapy
![Page 17: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/17.jpg)
Chemotherapy
Early breast cancer – Taxanes
• Paclitaxel• Docetaxel
– Dose-Dense • Every 2 weeks (compared to every 3 weeks
of regular therapy)– Neoadjuvant
![Page 18: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/18.jpg)
Neo-Adjuvant Chemotherapy
SURGERY
Neo-AdjuvantChemotherapy
AdjuvantRadiation
AdjuvantEndocrine
![Page 19: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/19.jpg)
Molecular Therapy
![Page 20: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/20.jpg)
Advances in Endocrine Therapy:“A Revolution in the Treatment of
Breast Cancer”
![Page 21: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/21.jpg)
Case No. 2
64-year-old female patient Recent dx of L sided breast cancer Mastectomy and axillary nodal dissection (AND) Pathology
– Tumour Size 1.2 cm– Tumour Grade II/III– Estrogen receptor +ve/progesterone receptor +ve
(hormone receptor +ve)– Lymph node negative (0/18)
![Page 22: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/22.jpg)
Case No. 2
What are the different treatment strategies available for this patient?
– Tamoxifen for 5 years
![Page 23: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/23.jpg)
Case No. 2
What are the benefits of tamoxifen? What are the toxicities related to tamoxifen?
![Page 24: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/24.jpg)
Tamoxifen: Improvement in Disease-Free Survival
Reprinted from The Lancet, vol 351, Early Breast Cancer Trialists’ Collaborative Group, 1451, 1998,with permission from Elsevier Science.
Years
100
% R
ecu
rren
ce-f
ree
90
80
60
40
20
05 10+0
Node -ve: 14.9% SD 1.4: 2P<0.00001Node +ve: 15.2% SD 2.5: 2P<0.00001
Node -ve
Node +ve
87.4
79.274.9
75.6 64.3
59.758.3
44.5
70
50
30
10
Absolute Recurrence Reduction
Tamoxifen (~5 y)
Placebo
Placebo
Tamoxifen (~5 y)
Recurrence as First Event
![Page 25: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/25.jpg)
Toxicity of Tamoxifen
Endometrial cancer Venous thrombosis Hot flashes Vaginal dryness/bleeding
![Page 26: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/26.jpg)
Case No. 2
What are the different treatment strategies available for this patient?
– Tamoxifen for 5 years– Aromatase inhibitor [AI] for 5 years– Tamoxifen for 2 -3 years followed by an AI to
complete 5 years of treatment– Tamoxifen for 5 years followed by an AI for 5
years
Winer et al. JCO 2005.
![Page 27: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/27.jpg)
Case No. 2: Further Questions
What is the mechanism of action of aromatase inhibitors?
What are the different classes of aromatase inhibitors?
Is there any evidence that aromatase inhibitors– Are better than tamoxifen?– Can be used within the first 5 years in sequence
with tamoxifen?
![Page 28: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/28.jpg)
Mechanism of Action
Smith et al. N Engl J Med 2004.
![Page 29: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/29.jpg)
Classes of Aromatase Inhibitors
Type 1(Steroidal Inactivator)
Type 2(Nonsteroidal Inhibitor)
• Exemestane (Aromasin) • Anastrozole (Arimidex)
• Letrozole (Femara)
![Page 30: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/30.jpg)
Tamoxifen vs. Aromatase Inhibitors in Early Breast Cancer
First Line
ATAC Trial (Anastrozole)
BIG 1-98 Trial (Letrozole)
![Page 31: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/31.jpg)
ATAC (Anastrozole)
ATAC Trialists’ Group. Lancet 2005.
+
Postmenopausal women with invasive breast cancerPostmenopausal women with invasive breast cancer
Surgery Surgery radiotherapy radiotherapy chemotherapy chemotherapy
Randomization 1:1:1 for 5 yearsRandomization 1:1:1 for 5 years
Anastrozole 1mg od+
Tamoxifen placebo
Anastrozole placebo+
Tamoxifen 20mg od
Anastrozole 1mg od+
Tamoxifen 20mg od
n=3125 n=3116 n=3125
![Page 32: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/32.jpg)
ATAC Trial (Anastrozole): Efficacy
Anastrazole shown to be superior to tamoxifen– Improved Disease Free Survival (DFS)– Contralateral breast cancer
No difference in Overall Survival (OS)
![Page 33: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/33.jpg)
BIG 1-98 Trial (Letrozole): Efficacy
Early results from this study show that– Letrozole is also superior to tamoxifen for
• Disease Free Survival• Distant recurrences (Systemic Disease Free
Survival)
![Page 34: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/34.jpg)
Aromatase Inhibitor Toxicity
In favour of Aromatase Inhibitors– Endometrial cancer– Vaginal bleeding/discharge– Thromboembolic disease
In favour of tamoxifen– Arthralgias– Osteoporosis
![Page 35: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/35.jpg)
Case No. 3
64-year-old female patient Hx of L sided breast cancer Original dx 2002 Mastectomy and AND Pathology
– Tumour Size: 1.2 cm– Tumour Grade: II/III– ER +ve/PR +ve– Lymph node negative (0/18)
On tamoxifen since 2002
![Page 36: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/36.jpg)
Case No. 3
The different treatment strategies available for this patient are
– Complete tamoxifen for 5 years– Tamoxifen for 2 years followed by exemestane
(an AI) to complete 5 years of therapy– Tamoxifen for 5 years followed by letrozole (an
AI) for another 5 years of therapy
![Page 37: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/37.jpg)
Switching From Tamoxifen to Aromatase Inhibitors
IES Trial (Exemestane)
![Page 38: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/38.jpg)
IES Schema
RRAANNDDOOMMIIZZAATTIIOONN
• Postmenopausal women
• Early ER+ breast cancer
• Disease free after adjuvant tamoxifen
20 mg po qd × 2-3 years
• 2-3 yearstamoxifen
20 mg po qd
• 2-3 yearsexemestane20 mg po qd
5 years total therapyCoombes et al. N Engl J Med 2004.
![Page 39: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/39.jpg)
IES Trial (Exemestane): Efficacy
Exemestane was superior to tamoxifen– Disease Free Survival (DFS)– Distant DFS
No difference in OS (Overall Survival)
![Page 40: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/40.jpg)
IES Trial (Exemestane):Toxicity
In favour of exemestane– Vaginal bleeding/discharge– Endometrial cancer– Thromboembolic disease
In favour of tamoxifen– Arthralgia– Osteoporosis
![Page 41: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/41.jpg)
Summary
Many options available for first-line treatment of hormone receptor positive early breast cancer
– Tamoxifen for 5 years, or– Anastrozole (AI) for 5 years, or– Letrozole (AI) for 5 years, or– Tamoxifen for 2 years followed by exemestane
(AI) to complete 5 years of therapy
Winer et al. JCO 2005.
![Page 42: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/42.jpg)
Summary (cont’d)
The optimal choice of therapy is dependent on – Patient’s underlying health– Tumour-related factors– Patient preference
![Page 43: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/43.jpg)
Extending Endocrine Treatment Beyond Five Years of Therapy
MA.17 Trial (Letrozole)
![Page 44: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/44.jpg)
Case No. 4
63-year-old female patient Hx of breast cancer, originally dx 5 years ago L lumpectomy and AND Pathology at that time:
– Tumour Size 2.5 cm – Tumour Grade III/III – Estrogen receptor +ve/progesterone receptor -ve– Lymph node 2/14 +ve
Followed by chemotherapy and radiation tx Received tamoxifen for 5 years Completed tx 2 months ago
![Page 45: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/45.jpg)
Case No. 4
What is her risk of recurrence now after completing 5 years of therapy with tamoxifen?
Should we keep her on tamoxifen longer?
![Page 46: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/46.jpg)
Recurrences Breast Cancer Deaths
More Than Half of Breast Cancer Recurrences and Deaths Occur Post-Tamoxifen
Adapted with permission. Early Breast Cancer Trialists’ Collaborative Group Meeting, 2000.
Years
85.2
76.1
68.2
73.7
62.7
54.9
68%
55%
0
20
40
60
80
100
0 5 10 15
TamoxifenControl
15% 17%
0
20
40
60
80
100
0 5 10 15
73%64%
80.9
73.087.8
73.2
64.064.0
Years
TamoxifenControl
9% 18%
91.4
% o
f p
atie
nts
% o
f p
atie
nts
![Page 47: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/47.jpg)
Case No. 4: Recurrence Risk
In this case situation, on average, – 70% of patients will be alive and without disease
at 5 years– There is still a 26% chance of relapse within
next 5 years
![Page 48: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/48.jpg)
NSABP B-14
Fisher et al. J Natl Cancer Inst 2001.
DFS
100
90
80
70
60
50
% o
f p
atie
nts
0 5
PlaceboTamoxifen
Years7
OS
0 5Years
100
90
80
70
60
507
% o
f p
atie
nts
PlaceboTamoxifen
Tamoxifen demonstrated higher rates of endometrial cancer, ischemicheart disease, and cerebrovascular disease.
82%
78%
94%
91%
P=0.03
P=0.07
1 2 4 63 1 32 4 6
No benefit of extending tamoxifenbeyond 5 years of therapy
![Page 49: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/49.jpg)
Case No. 4
Are there other therapeutic options available for this patient?
![Page 50: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/50.jpg)
Extended adjuvant letrozole
Adjuvant tamoxifen
Rationale for the MA.17 Extended Adjuvant Trial
Lack of benefit when adjuvant tamoxifen treatment is extended beyond 5 years
Increasing risk for long-term adverse effects (thromboembolism, endometrial hyperplasia/cancer, hot flashes, vaginal/urinary symptoms)
Need to extend DFS/OS beyond adjuvant tamoxifen
Goss et al. N Engl J Med 2003.
![Page 51: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/51.jpg)
Trial Design of MA.17
Goss et al. N Engl J Med 2003.
Randomization(All patients disease-free)
Tamoxifen
Placebo qd
Letrozole 2.5 mg qd
Approx. 5 years adjuvant 5 years extended adjuvant
0–3months n=2575
n=2582
![Page 52: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/52.jpg)
Letrozole (MA.17) Efficacy
Letrozole was superior to placebo– DFS (Disease Free Survival)– Distant DFS– Overall Survival
• difference in Lymph Node positive patients only
![Page 53: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/53.jpg)
P=0.04
Node-Positive Node-Negative
P=0.24
Overall Survival MA.17
0
20
40
60
80
100
Time from randomization (months) 0
12921276
10
12651250
20
972964
30
572571
40
275283
50
9393
60
35
0
20
40
60
80
100
Time from randomization (months)
Femara Placebo
0
11711189
10
11441157
20
875877
30
508500
40
255243
50
8175
60
33
Per
cen
t
Letrozole Placebo
Per
cen
t
Letrozole Placebo
No. at Risk
Adapted from Goss. ASCO 2004.
While OS was not improved in node-negative patients, a similar reductionin local recurrences, new primaries, and distant recurrences occurred as in
the node-positive patients
![Page 54: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/54.jpg)
Letrozole (MA.17) Toxicity
Letrozole compared to placebo Letrozole therapy associated with
– Hot flashes– Vaginal bleeding/discharge– Osteoporosis
Adapted from Goss. ASCO 2004.
![Page 55: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/55.jpg)
Case No. 4: Summary
Patients such as in this case, who have completed 5 years of therapy on tamoxifen, should
– Be referred back to the cancer centre The medical oncologist will discuss extended therapy
for these patients This discussion may involve
– Recurrence risk– Patient’s co-morbidities– Patient preference
![Page 56: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/56.jpg)
Summary: Use of Aromatase Inhibitors
Aromatase inhibitors in adjuvant setting– Literature specific for post-menopausal women– Effective in preventing recurrence, reduction in
distant metastasis and new contralateral breast cancer
– Effective as first-line adjuvant, sequence, and extended therapy
– Overall survival improvement seen only in node-positive patients with 5 years of letrozole in the extended setting
– Long-term safety data remains to be studied
![Page 57: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/57.jpg)
Best Adjuvant Strategy: Remains to be Seen
Aromatase inhibitors– As neoadjuvant?– After 2-3 yrs of tamoxifen?– after 5 yrs of tamoxifen?– after 5 yrs of AI therapy?– Duration of AI therapy?– Only for high-risk breast cancer?
![Page 58: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/58.jpg)
Follow-Up of Patientswith History of Breast Cancer
![Page 59: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/59.jpg)
Early Breast Cancer Treatment Schema
SURGERY
AdjuvantChemotherapy
AdjuvantRadiation
AdjuvantEndocrine
Follow-Up
![Page 60: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/60.jpg)
Case No. 5
54-year-old female patient Dx with early stage breast cancer 2 years ago Received chemotherapy with an anthracycline-
containing regimen (CEF)– Cyclophosphamide– Epirubicin– Fluorouracil
![Page 61: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/61.jpg)
Case No. 5
What is the role of family physicians (FPs) in following these patients?
Why is it important to follow patients with previous history of breast cancer?
What are the requirements for appropriate follow-up?
![Page 62: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/62.jpg)
Role of Family Physician
FPs remain the primary care givers for most of these patients
FPs may provide follow-up as– Sole provider of care– In conjunction with the cancer centre
![Page 63: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/63.jpg)
Who Should Do the Follow-up?
Ontario Study– Randomized breast cancer follow-up to
• Cancer centres• Family physicians
Results– No difference in patient outcome
• Serious clinical events
Grunfeld et al. PASCO 2004.
![Page 64: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/64.jpg)
Why Follow Patients?
Follow-up may help– Provide adequate psychosocial support and
counseling– Detect recurrent and metastatic disease– Detect other malignancies– Monitor toxicities related to current or previous
treatment
![Page 65: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/65.jpg)
Canadian Steering CommitteeGoals of Follow-Up
Three major objectives of follow-up care– Support and counseling– Detection of disease relapse locally and distant– Surveillance for second malignancies
![Page 66: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/66.jpg)
Frequency of Follow-Up
Bari Consensus Conference (1995) recommendations
– Visits every 3 months for the first 2 years, then– Every 6 months for the next 3 years, then – Annually thereafter
![Page 67: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/67.jpg)
Available Guidelines
Canadian Steering Committee on Clinical Practice Guidelines (Canadian Task Force)
American Society of Clinical Oncology (ASCO)
Canadian Steering Committee on Clinical Practice Guidelines. CMAJ 1999.American Society of Clinical Oncology. JCO 1998.
![Page 68: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/68.jpg)
Summary of Guidelines
History and physical– Every 3-6 months first 3 yrs after primary
therapy– Then q 6 months for 2 yrs– Then annually
Annual mammogram Encourage monthly BSE Educate re: recurrence symptoms Regular pelvic exams
Canadian Steering Committee on Clinical Practice Guidelines. CMAJ 1999.American Society of Clinical Oncology. JCO 1998.
![Page 69: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/69.jpg)
Summary of GuidelinesDo Not Do Routinely
CBC, renal function tests, liver function tests, albumin, protein, calcium
Chest X-ray Bone scan Liver ultrasound CT Tumour markers: CEA, CA 15-3
Canadian Steering Committee on Clinical Practice Guidelines. CMAJ 1999.American Society of Clinical Oncology. JCO 1998.
![Page 70: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/70.jpg)
Follow-up for Breast Cancer Patients On Endocrine Therapies
Bloodwork– No need for routine blood work
Bone mineral density (BMD)– Of particular importance for patients on
aromatase inhibitors • Recommend baseline, then annually
![Page 71: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/71.jpg)
Follow-up for Breast Cancer Patients On Endocrine Therapies (cont’d)
Ophthalmologic evaluation– Symptom driven– If previous history – annual exam
No role for other routine investigations – Including pelvic or abdominal U/S, Doppler, etc.
![Page 72: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/72.jpg)
Common Health Issues Among Breast Cancer Patients
![Page 73: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/73.jpg)
Common Health Issues
Cardiac toxicity Osteoporosis Early menopause Secondary cancers
![Page 74: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/74.jpg)
Case No. 5 (cont’d)
Patient now has increasing SOB with exertion– What other features on history and physical
examination are important?– What investigations are critical to help us with
the diagnosis?
![Page 75: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/75.jpg)
Cardiac Toxicity –Chemotherapy Related
Anthracyclines– Daunorubicin, doxorubicin, idarubicin, epirubicin,
and mitoxantrone Toxicity effects
– Acute (during administration)• Arrythmias, pericarditis-myocarditis
– Early (Several days to mos following)• CHF, with peak at 3 mos after last dose
– Late (years to decades following)• CHF may develop up to 10-12 yrs after last
anthracyline dose
![Page 76: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/76.jpg)
Cardiac Toxicity – Anthracyclines
Risk factors for the development of anthracycline cardiac toxicity
– Cumulative dose – strongest risk factor– Age– Prior irradiation– Concomitant administration of other agents– Previous history of cardiac disease
![Page 77: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/77.jpg)
Cardiac Toxicity – Other Therapies
Aromatase inhibitors– Long-term cardiac toxicity remains to be studied
with these agents Herceptin
![Page 78: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/78.jpg)
Osteoporosis
Hormone-dependent osteoporosis– Early menopause– Chemotherapy-induced premature ovarian
failure– Endocrine treatment
Hormone-independent osteoporosis– Direct effect of chemotherapy– History of breast cancer
![Page 79: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/79.jpg)
Management of Osteoporosis forPatients on Aromatase Inhibitors
Surveillance– Annual BMD– Height measurements
• If needed: T + L Spine X-rays– Risk factor assessment
Therapy– Bone hygiene
• Calcium 1500 mg/d + Vitamin D 800 I.U. supplement– Bisphosphonate therapy
• Early initiation of bisphosphonate therapy if» BMD t score <2.5» Progressive bone loss
Hillner et al. JCO 2003.
![Page 80: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/80.jpg)
Early Menopause
Fertility issues Menopausal symptoms
– Treatment related– Non-treatment related
Osteoporosis (previously discussed)
![Page 81: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/81.jpg)
Secondary Cancers
Incident case Breast cancer
– New primary cancer• Risk about 1%
per year– Recurrence
• Local• Metastatic
Other cancers Treatment independent Secondary to treatment
– Chemotherapy– Radiation – Endocrine
![Page 82: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/82.jpg)
Other Concerns
Lymphoedema– Referrals to supportive care services
Family members– Screening for breast cancer– Screening for other cancers– Genetic assessment
![Page 83: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/83.jpg)
Case No. 5 (cont’d)
Patient now presents with back pain over the last 4 months
Pain located in lower thoracic/upper lumbar area
![Page 84: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/84.jpg)
Case No. 5 (cont’d)
When should the FP refer the patient back to the cancer centre?
What are some concerning symptoms associated with back pain?
What are the common sites of distant metastasis? How should we investigate?
![Page 85: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/85.jpg)
When Should FPs ReferPatients to Cancer Centre?
Cancer related– New breast lump or local lymphadenopathy
• New primary breast cancer• Cancer recurrence
– Concerning distant symptoms– Secondary cancers
![Page 86: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/86.jpg)
When Should FPs Specifically Consult Medical Oncology?
Treatment related– New endocrine treatment for follow-up
population– Toxicities– Patient driven
![Page 87: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/87.jpg)
Early Breast CancerRole of Family Physicians
SURGERY
AdjuvantChemotherapy
AdjuvantRadiation
AdjuvantEndocrine
Follow-Up
Family physicians
![Page 88: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/88.jpg)
Conclusions
There have been some key advances in the management of breast cancer in the last few years
Regular and appropriate follow-up care is essential for patients with history of breast cancer
![Page 89: Breast Cancer Patient Issues in Family Practice: An Interactive Session](https://reader035.fdocuments.in/reader035/viewer/2022062305/568151c1550346895dbff6e7/html5/thumbnails/89.jpg)
Conclusions
Family physicians play an integral role in the management of these patients
It is important to refer patients to cancer centre – To evaluate any specific concerns, or – To review if they are suitable candidates for new
therapies